Hypertensive disease
Chronic care startup Omada Health files to go public
Chronic care management, virtual care, IPO, digital health, diabetes management, cardiometabolic health, hypertension, musculoskeletal conditions, revenue growth, Hinge Health
Mineralys Phase 3 blood pressure pill data support potential FDA approval
United States Food and Drug Administration, Launch-HTN, Uncontrolled, Hypertensive disease, Approved
Novo Nordisk Pursues $830 Million Fraud Claim Against KBP Biosciences Over Failed Hypertension Drug
Novo Nordisk, KBP Biosciences, ocedurenone, fraud, asset freeze, clinical trial failure, hypertension drug, arbitration
NFL Legend Jerome Bettis Joins CDC Foundation’s “Live to the Beat” Campaign to Tackle Heart Health in Black Community
Jerome Bettis, CDC Foundation, Live to the Beat, cardiovascular disease, Black community, hypertension, heart health, NFL
Idorsia’s Restructuring Efforts Continue: Layoffs On Track Despite Delayed Sale of Hypertension Drug Tryvio
Idorsia, Restructuring, Layoffs, Tryvio, Hypertension drug, Aprocitentan, Cost-saving measures, Financial sustainability
Novo Nordisk Terminates Development of Kidney Disease Drug Ocedurenone After Phase 3 Failure
Novo Nordisk, ocedurenone, kidney disease, hypertension, Phase 3 trial, CLARION-CKD, drug development failure
CMS Approves Transitional Pass-Through Payments for Renal Denervation Systems from Medtronic and Recor Medical
Renal Denervation Systems, CMS, Transitional Pass-Through Payments, Medtronic, Recor Medical, Hypertension Treatment
George Medicines Unveils Promising Low-Dose Triple Combination Pill for Hypertension Management
Hypertension, Triple Combination Pill, Low-Dose, Blood Pressure Control, GMRx2, George Medicines
Evaluating the Impact of a Dose-Optimization App on Zestril Efficacy for Hypertension Management
Zestril, hypertension, dose-optimization, app, closed-loop testing, efficacy, blood pressure management.
Roche and Alnylam’s Hypertension Hopeful Zilebesiran Shows Promising Results in Combination Therapy Trial
Roche, Alnylam, Zilebesiran, Hypertension, Combination Therapy, Phase 2 Trial, Blood Pressure Control, AngioTensinogen (AGT), RNA Interference (RNAi) Therapeutic, Significant Reductions in Systolic Blood Pressure, Encouraging Safety Profile